Table 2.
Guideline-directed medical therapy use between groups.
| MOC at baseline (n = 1419) |
Control at baseline (n = 5116) |
p-value | MOC at discharge or last visit (n = 1419) |
Control at last visit (n = 5116) |
p-value | |
|---|---|---|---|---|---|---|
| GDMT medications | ||||||
| Quadruple therapy | 243 (17.1 %) | 350 (6.8 %) | <0.0001 | 691 (48.7 %) | 957 (18.7 %) | <0.0001 |
| ARNi | 565 (39.8 %) | 1492 (29.2 %) | <0.0001 | 872 (61.5 %) | 2252 (45.1 %) | <0.0001 |
| <50 % target dose | 457 (80.9 %) | 1141 (76.5 %) | 522 (59.9 %) | 2053 (91.2 %) | ||
| 50 to <100 % target dose | 94 (16.6 %) | 260 (17.4 %) | 324 (37.2 %) | 137 (6.1 %) | ||
| Target dose | 14 (2.5 %) | 91 (6.1 %) | 26 (3 %) | 62 (2.8 %) | ||
| ACEi | 297 (20.9 %) | 1988 (38.9 %) | <0.0001 | 156 (11 %) | 1079 (21.1 %) | <0.0001 |
| <50 % target dose | 163 (54.9 %) | 1043 (52.5 %) | 110 (70.5 %) | 599 (55.5 %) | ||
| 50 to <100 % target dose | 53 (17.8 %) | 396 (19.9 %) | 6 (3.8 %) | 241 (22.3 %) | ||
| Target dose | 81 (27,3 %) | 549 (27.6 %) | 40 (25.6 %) | 239 (22.2 %) | ||
| ARB | 294 (20.7 %) | 1124 (22 %) | 0.3125 | 220 (15.5 %) | 897 (17.5 %) | 0.071 |
| <50 % target dose | 252 (85.7 %) | 865 (77 %) | 190 (86.4 %) | 842 (93.9 %) | ||
| 50 to <100 % target dose | 37 (12.6 %) | 234 (20.8 %) | 28 (12.7 %) | 40 (4.5 %) | ||
| Target dose | 5 (1.7 %) | 25 (2.2 %) | 2 (0.9 %) | 15 (1.7 %) | ||
| BB | 1221 (86 %) | 4257 (83.2 %) | 0.01 | 1313 (92.5 %) | 4517 (88.3 %) | <0.0001 |
| <50 % target dose | 906 (74.2 %) | 3284 (77.1 %) | 810 (61.7 %) | 3303 (73.1 %) | ||
| 50 to <100 % target dose | 253 (20.7 %) | 870 (20.4 %) | 382 (29.1 %) | 1002 (22.2 %) | ||
| Target dose | 62 (5.1 %) | 103 (2.4 %) | 121 (9.2 %) | 212 (4.7 %) | ||
| MRA | 619 (43.6 %) | 1814 (35.5 %) | <0.0001 | 974 (68.6 %) | 2319 (45.3 %) | <0.0001 |
| <50 % target dose | 3 (0.5 %) | 14 (0.8 %) | 1 (0.1 %) | 3 (0.1 %) | ||
| 50 to <100 % target dose | 84 (13.6 %) | 252 (13.9 %) | 59 (6.1 %) | 163 (7 %) | ||
| Target dose | 532 (85.9 %) | 1548 (85.3 %) | 914 (93.8 %) | 2153 (92.8 %) | ||
| SGLT2i | 491 (34.6 %) | 724 (14.2 %) | <0.0001 | 970 (68.4 %) | 1813 (35.4 %) | <0.0001 |
ARNi = angiotensin-receptor neprilysin inhibitor; ACEi = angiotensin-converting enzyme inhibitor; ARB = angiotensin receptor blocker; BB = beta-blocker (e.g., bisoprolol, carvedilol, metoprolol succinate); MRA = mineralocorticoid receptor antagonist; SGLT2i = sodium-glucose cotransporter-2 inhibitor (e.g., dapagliflozin, empagliflozin).
Data expressed as n (%).
Target doses defined as an increase to a dose at or above daily guideline recommendations, among patients taking less than the target dose.